Brief: Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025
15/05/2025 06:14
May 15 (Reuters) - BioArctic AB BIOAb.ST: EISAI PROJECTS LEQEMBI® REVENUE TO TOTAL JPY 76.5 BILLION FOR FISCAL YEAR 2025 (APRIL 2025 - MARCH 2026) BIOARCTIC AB - EXPECTED TO RECEIVE SEK 510 M IN ROYALTY FROM LEQEMBI SALES Source text: ID:nWkr2CvvfT Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln